Dura substitute guidance
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers of animal derived dura substitutes should provide information on the species and animal from which the substitute was derived, Nov. 9 FDA guidance recommends. Firms should also answer questions on how the health of the herd is maintained and monitored, the document states. In 1999, FDA's Neurological Devices Panel recommended that one-year follow-up imaging was of limited clinical value in performance assessments (1"The Gray Sheet" Sept. 27, 1999, p. 9)
You may also be interested in...
Dura Substitute 510(k)s Should Not Require Follow-Up Imaging - FDA Panel
One-year follow-up imaging in patients with implanted dura substitute devices has little clinical value in performance assessment, members of FDA's Neurological Devices Panel agreed at a Sept. 16 meeting in Gaithersburg, Maryland.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.